These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17714157)

  • 41. Tacrolimus is not a preventive agent for occupational skin diseases.
    Jungbauer F; Coenraads PJ
    J Am Acad Dermatol; 2007 Mar; 56(3):519-20; author reply 520. PubMed ID: 17317492
    [No Abstract]   [Full Text] [Related]  

  • 42. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients.
    Reitamo S; Rustin M; Harper J; Kalimo K; Rubins A; Cambazard F; Brenninkmeijer EE; Smith C; Berth-Jones J; Ruzicka T; Sharpe G; Taieb A;
    Br J Dermatol; 2008 Sep; 159(4):942-51. PubMed ID: 18637898
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lichenoid tattoo reaction responding to topical tacrolimus ointment.
    Campbell FA; Gupta G
    Clin Exp Dermatol; 2006 Mar; 31(2):293-4. PubMed ID: 16487120
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty.
    Dhaliwal JS; Mason BF; Kaufman SC
    Cornea; 2008 May; 27(4):488-93. PubMed ID: 18434855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eosinophilic pustular folliculitis: successful treatment with topical pimecrolimus.
    Rho NK; Kim BJ
    Clin Exp Dermatol; 2007 Jan; 32(1):108-9. PubMed ID: 17305916
    [No Abstract]   [Full Text] [Related]  

  • 46. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial.
    Radakovic S; Breier-Maly J; Konschitzky R; Kittler H; Sator P; Hoenigsmann H; Tanew A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):951-3. PubMed ID: 19496898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis.
    Wollenberg A; Sidhu MK; Odeyemi I; Dorsch B; Koehne-Volland R; Schaff M; Ehlken B; Berger K
    Br J Dermatol; 2008 Dec; 159(6):1322-30. PubMed ID: 18782316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety concerns for two eczema drugs.
    FDA Consum; 2005; 39(3):5. PubMed ID: 16130203
    [No Abstract]   [Full Text] [Related]  

  • 49. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.
    Thaçi D; Reitamo S; Gonzalez Ensenat MA; Moss C; Boccaletti V; Cainelli T; van der Valk P; Buckova H; Sebastian M; Schuttelaar ML; Ruzicka T;
    Br J Dermatol; 2008 Dec; 159(6):1348-56. PubMed ID: 18782319
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term efficacy of tacrolimus ointment in severe uremic pruritus.
    Pauli-Magnus C; Klumpp S; Alscher DM; Kuhlmann U; Mettang T
    Perit Dial Int; 2000; 20(6):802-3. PubMed ID: 11216583
    [No Abstract]   [Full Text] [Related]  

  • 51. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis.
    Kymionis GD; Goldman D; Ide T; Yoo SH
    Cornea; 2008 Feb; 27(2):228-9. PubMed ID: 18216583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment.
    Wollenberg A; Reitamo S; Girolomoni G; Lahfa M; Ruzicka T; Healy E; Giannetti A; Bieber T; Vyas J; Deleuran M;
    Allergy; 2008 Jul; 63(7):742-50. PubMed ID: 18592619
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tacrolimus hydrate ointment inhibits skin plasma extravasation in rats induced by topical m-xylene but not capsaicin.
    Goto S; Kondo F; Ikai Y; Miyake M; Futamura M; Ito K; Sakamoto T
    Eur J Pharmacol; 2009 Apr; 608(1-3):91-6. PubMed ID: 19258015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle.
    Breneman D; Fleischer AB; Abramovits W; Zeichner J; Gold MH; Kirsner RS; Shull TF; Crowe AW; Jaracz E; Hanifin JM;
    J Am Acad Dermatol; 2008 Jun; 58(6):990-9. PubMed ID: 18359127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment.
    Sánchez Regaña M; Márquez Balbás G; Umbert Millet P
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):963-9. PubMed ID: 18410337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Ivosin ointment in chrome-induced eczema].
    Neuman E
    Przegl Dermatol; 1976; (6 Suppl):167-70. PubMed ID: 146223
    [No Abstract]   [Full Text] [Related]  

  • 57. Efficacy and safety of tarcrolimus cream 0.1% in the treatment of vitiligo.
    Xu AE; Zhang DM; Wei XD; Huang B; Lu LJ
    Int J Dermatol; 2009 Jan; 48(1):86-90. PubMed ID: 19126059
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Can tacrolimus ointment (Protopic) exacerbate an intercurrent fungal infection?
    Bronstein DE; Cherry JD
    Pediatrics; 2006 Jun; 117(6):2325-6; author reply 2326. PubMed ID: 16740887
    [No Abstract]   [Full Text] [Related]  

  • 59. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis.
    Reitamo S; Mandelin J; Rubins A; Remitz A; Mäkelä M; Cirule K; Rubins S; Zigure S; Ho V; Dickinson J; Undre N
    Int J Dermatol; 2009 Apr; 48(4):348-55. PubMed ID: 19335418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Granuloma faciale successfully treated with topical tacrolimus.
    Patterson C; Coutts I
    Australas J Dermatol; 2009 Aug; 50(3):217-9. PubMed ID: 19659988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.